Page last updated: 2024-11-11

montirelin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

montirelin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6917793
CHEBI ID31864
SCHEMBL ID194391
MeSH IDM0099978

Synonyms (35)

Synonym
ps-24
cnk-602a
montirelin
cg-3703
D02588
90243-66-6
montirelin (inn)
montirelinum [latin]
(-)-n-(((3r,6s)-6-methyl-5-oxo-3-thiomorpholinyl)carbonyl)-l-histidyl-l-prolinamide
cnk 602a
cnk-603
n-(((3r,6r)-6-methyl-5-oxo-3-thiomorpholinyl)carbonyl)-l-histidyl-l-prolinamide
l-prolinamide, (3r,6r)-6-methyl-5-oxo-3-thiomorpholinecarbonyl-l-histidyl-
ns 3
l-prolinamide, (2r)-2-mercaptopropanoyl-l-cysteinyl-l-histidyl-, cyclic (1-2)-sulfide
montirelina [spanish]
montireline [french]
l-prolinamide, n-((6-methyl-5-oxo-3-thiomorpholinyl)carbonyl)-l-histidyl-, (3r-cis)-
cg 3703
(3r-cis)-n-((6-methyl-5-oxo-3-thiomorpholinyl)carbonyl)-l-histidyl-l-prolinamide
montirelin [inn]
ccris 7571
(3r,6r)-n-[(2s)-1-[(2s)-2-carbamoylpyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]-6-methyl-5-oxothiomorpholine-3-carboxamide
ns-3
30muj6yyuy ,
montirelina
montirelinum
unii-30muj6yyuy
montireline
SCHEMBL194391
CHEBI:31864
(3r,6r)-n-((s)-1-((s)-2-carbamoylpyrrolidin-1-yl)-3-(1h-imidazol-4-yl)-1-oxopropan-2-yl)-6-methyl-5-oxothiomorpholine-3-carboxamide
Q27255963
DTXSID301034132
AKOS040753132

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" These results show that the lethal dose of CNK-603 is over 4 times lower than that of montirelin hydrate, and that CNK-6004 is less toxic than montirelin hydrate."( [Single dose toxicity studies of metabolite, degradation product and impurity of montirelin hydrate (NS-3) in mice].
Hagidai, Y; Iwakura, K; Nakazawa, M; Nishiguchi, Y; Oka, T; Sumi, N, 1995
)
0.74
" The drug had no adverse effects on reproductive function of the parent animals, or on development of fetuses."( [Reproductive and developmental toxicity studies of montirelin hydrate (1)--Fertility study in rats by intravenous administration].
Fujii, S; Furukawa, S; Kikumori, M; Morinaga, T; Sumi, N; Watanabe, M; Yasuhira, K, 1995
)
0.54
" The drug did not have any adverse effects on the newborn such as the number of live newborns, birth index and body weights of live newborn, or on the postnatal development of the first generation offspring (F1) such as differentiation, functional development, emotionality, motor ability, learning ability or reproductive performance."( [Reproductive and developmental toxicity studies of montirelin hydrate (2)--Teratogenicity and postnatal study in rats by intravenous administration].
Furukawa, S; Kikumori, M; Morinaga, T; Sumi, N; Toteno, I; Watanabe, M; Yasuhira, K, 1995
)
0.54
" The drug did not have any adverse effects on the newborn including the number of live newborns, birth index and body weights of live newborn."( [Reproductive and developmental toxicity studies of montirelin hydrate (4)--Perinatal and postnatal study in rats by intravenous administration].
Fujii, S; Kikumori, M; Morinaga, T; Nishimori, T; Sumi, N; Watanabe, M, 1995
)
0.54

Pharmacokinetics

ExcerptReferenceRelevance
" During repeated once daily administration for 10 days, the radioactivity concentration in the plasma 24 h after each administration reached practically steady state level after the 7th administration and decreased with a half-life of 38."( Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 2nd communication: distribution and transfer into the fetus and milk after a single intravenous administration and pharmacokinetics and enzyme induction after repeated
Hayashi, T; Morino, A; Okita, A; Sugimoto, T, 1996
)
0.53

Dosage Studied

ExcerptRelevanceReference
" The body weight, food consumption and water consumption, and pathological findings showed no changes attributable to the dosing of montirelin hydrate in any animal."( [Single dose toxicity studies of montirelin hydrate(NS-3) in mice, rats and dogs].
Iwakura, K; Kikumori, M; Nagasawa, H; Nakai, N; Nishida, I; Nishiguchi, Y; Nishimura, T; Sumi, N; Yasuhira, K, 1995
)
0.78
" The body weight showed no changes attributable to the dosing of the two compounds in mice."( [Single dose toxicity studies of metabolite, degradation product and impurity of montirelin hydrate (NS-3) in mice].
Hagidai, Y; Iwakura, K; Nakazawa, M; Nishiguchi, Y; Oka, T; Sumi, N, 1995
)
0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oligopeptideA peptide containing a relatively small number of amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (59)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (22.03)18.7374
1990's43 (72.88)18.2507
2000's3 (5.08)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.66 (24.57)
Research Supply Index4.13 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other61 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]